CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
3 research outputs found
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Author
Brian Caveney
Chiara Chiruzzi
+8 more
Eric A. Severson
Heidi Ko
Jonathan Klein
Kamal S. Saini
Kyle C. Strickland
Marcia Eisenberg
Rebecca A. Previs
Shakti Ramkissoon
Publication venue
Adis, Springer Healthcare
Publication date
01/11/2023
Field of study
No full text
Directory of Open Access Journals
Recommended from our members
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Author
Caveney Brian
Chiruzzi Chiara
+8 more
Eisenberg Marcia
Klein Jonathan
Ko Heidi
Previs Rebecca A
Ramkissoon Shakti
Saini Kamal S
Severson Eric A
Strickland Kyle C
Publication venue
Oncol Ther
Publication date
22/02/2024
Field of study
No full text
Apollo (Cambridge)
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
Author
Alessandra Di Pietro
Brian I. Rini
+8 more
Chiara Chiruzzi
Fiona Thistlethwaite
James M. G. Larkin
Marcella Martignoni
Michael S. Gordon
Michael Shnaidman
Paul D. Nathan
Toni K. Choueiri
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
No full text
No full textNo full text